Vaxxed vs Unvaxxed Neurodevelopmental Outcomes in COVID Jabbed Children

October 9, 2026

Please remember, the COVID injections are NOT vaccines. They are a gene therapy developed by the military that have never protected against infection or transmission. They weren’t even tested for reduction in hospitalization, death, or transmission. They were tested for reduction in severe symptoms – which is not the proper endpoint for “vaccine” efficacy. The public, which has served as subjects in an ongoing clinical trial for an experimental mRNA platform never before used in humans, that scientists have admitted have toxicity risks, is suffering from catastrophic injuries and death, but ‘the powers that be’ simply target those for speaking the truth: the COVID shots are killing people.

https://zenodo.org/records/23165256

Published October 5, 2026 | Version v1

Preprint Open

Neurodevelopmental Outcomes in COVID-19-Vaccinated Versus Unvaccinated U.S. Children: Analysis of the National Health Interview Survey, 2022–2024

Authors/Creators
Description
Abstract

Background: Autism spectrum disorder now affects 1 in 31 U.S. 8-year-olds and continues to rise at an alarming rate. COVID-19 mRNA vaccines were first authorized for U.S. children aged 12–15 in May 2021, 5–11 in October 2021, and 6 months–4 years in June 2022. No pediatric trial or post-marketing surveillance study was designed or powered to detect neurodevelopmental or mental-health outcomes after childhood COVID-19 mRNA vaccination. Vaccine-derived spike protein circulates systemically after vaccination and has been detected in blood, monocytes, cerebral arteries, and peripheral tissue months to years later, the S1 subunit disrupts blood–brain-barrier integrity in vitro, and prenatal spike-protein exposure induces autism-like behavior, neuroinflammation, and reduced BDNF in male rats. A population-level signal-detection analysis is warranted.

Methods: We pooled the 2022–2024 National Health Interview Survey (NHIS) Sample Child files (n = 21,990 children aged 0–17 with COVID-19 vaccination status; n = 19,882 aged 2–17 for autism, ADHD, and learning-disability items; 844 lifetime and 779 current ASD cases), with the 2021 (ages 12–17) and 2025 (current-season dose) files as supplementary samples. The primary comparison was COVID-19-vaccinated versus COVID-19-unvaccinated children (parental report of ever receiving a COVID-19 vaccine; “unvaccinated” denotes no COVID-19 vaccine, not absence of routine childhood immunization), with number of doses and years since first dose as secondary exposures. Outcomes were parent-reported lifetime and current autism spectrum disorder (ASD), ADHD, learning disability, intellectual disability, developmental delay, special-education use, asthma, diabetes, anxiety and depression frequency, mental-health treatment, general health, and acute-care use. Influenza and HPV vaccination served as negative-control exposures. Survey-weighted logistic regression with stratum/PSU Taylor-linearized variance estimated odds ratios (ORs) across five adjustment tiers.

Results: Compared with unvaccinated children, COVID-19-vaccinated children had higher adjusted odds of lifetime ASD (aOR 1.26, 95% CI 1.04–1.52), current ASD (1.32, 1.08–1.60), ADHD (1.33, 1.18–1.49), any neurodevelopmental diagnosis (1.23, 1.12–1.35), special-education use (1.19, 1.08–1.31), asthma (1.24, 1.11–1.37), daily/weekly anxiety (1.27, 1.15–1.42), and mental-health medication (1.57, 1.38–1.77) and therapy (1.60, 1.43–1.79); the E-value for current ASD was 1.97, and no measured covariate was associated with both vaccination and autism in the same direction at this magnitude. Adjusted odds rose monotonically with dose count (current ASD 1.03, 1.25, 1.40 for 1, 2, ≥3 doses vs 0). The association (current ASD) was largest in the youngest exposed cohort: ≥3 doses vs 0 at ages 5–7, aOR 2.54 (1.33–4.84); ages 2–7, 2.37 (1.38–4.10); and among children first vaccinated at age ≤5 at least one year before interview, 2.46 (1.08–5.62; 9 exposed cases). Under propensity-score overlap weighting, which eliminated all measured covariate imbalance, the autism association was unchanged and remained significant (lifetime 1.23, 1.01–1.50; current 1.26, 1.03–1.56), while the negative-control outcomes of emergency-department visits and hospitalization were close to the null (0.95 and 1.02). Estimates were unchanged after restriction to children without asthma, diabetes, or fair/poor health (n = 16,803; both vaccines vs neither, 1.51, 1.17–1.95), and persisted after additional adjustment for emergency-department use, hospitalization, and prescription use (1.31, 1.04–1.66). In direct comparison, COVID-19-vaccine-only children (n = 3,205) had higher odds of ASD than influenza-vaccine-only children (n = 3,763; 1.45, 1.03–2.05) despite lower odds of asthma (0.73) and emergency-department visits (0.77). Anxiety showed partial specificity (COVID-19 vaccine 1.34 vs influenza vaccine 1.07 at ages 5–11). Against the unvaccinated reference; however, influenza-vaccine-only and COVID-19-vaccine-only, point estimates were similar and modest (1.11 and 1.12) for ASD. Likewise, HPV vaccination was modestly associated with ASD 1.17 (0.74–1.85). The ASD association was amplified among children receiving both (influenza and COVID-19) vaccines (1.42–1.51). Associations for current ASD weakened with time since first dose, and the COVID-19 vaccine association was confined to girls (1.60 vs boys 1.08; interaction p = 0.02).

Conclusions: In a direct comparison of COVID-19-vaccinated with unvaccinated children in a nationally representative U.S. sample, COVID-19 vaccination was associated with higher adjusted odds of autism, ADHD, anxiety, special-education use, and mental-health treatment. The autism association persisted across every adjustment tier; was unchanged under propensity-score balancing that removed all measured covariate imbalance and nullified the acute-care negative controls; was robust to restriction to physically healthy children; increased monotonically with dose count; was largest in the youngest exposed cohorts, including children vaccinated before the school-entry diagnostic window; and exceeded that of influenza vaccination in direct comparison. These properties satisfy the strength, consistency, biological gradient, plausibility, and coherence considerations for causal inference, and no measured confounder explains them. Because the cross-sectional design cannot order exposure and diagnosis, a global scheduled combination childhood vaccine effect on neurodevelopment cannot be evaluated. A linked birth-cohort study of toddlers before age 3 capturing co-administered vaccines, incident diagnoses, and pre-specified negative controls would be the next step in evaluating this concerning association. (See link for full study)

__________________

**Comment**

For more:

Category:

Activism, research, vaccines, Viruses

Comments Off on Vaxxed vs Unvaxxed Neurodevelopmental Outcomes in COVID Jabbed Children